source
- Summit Therapeutics shares two-year survival data for its experimental cancer drug ivonescimab in Western patientsSummit Therapeutics presented new two-year overall survival results for its experimental antibody ivonescimab in Western participants of its global Phase 3 trial. The data were released alongside…
- Celldex halts development of mast cell antibody after Phase 2 failure in prurigo nodularisCelldex announced it will discontinue the clinical program for its mast cell‑targeting monoclonal antibody aimed at treating prurigo nodularis, a chronic itchy‑skin condition. The decision follows…